A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Antitumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Anti-PD-1 in Patients with Metastatic Solid Tumors
LYT-200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors
Sponsor: PureTech Health
Enrolling: Male and Female Patients
IRB Number: AAAT5289
U.S. Govt. ID: NCT04666688
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This is the first research study of LYT-200 in people and the main purpose of this study is to test the safety and tolerability of LYT-200. LYT-200 is intended to inhibit (hinder) galectin 9. Galectin 9 is a protein which suppresses immune function and disables the immune systems attack on cancer through multiple ways. In this study we shall also examine how the drug is changed by and removed from the body and will look for signs that the drug may be truly effective against cancer. Cancers include: Colon cancer, rectal cancer, liver cancer, lung cancer, and pancreatic cancer.
Investigator
Gulam Manji, MD, PhD
Do You Qualify?
Are you age 18 or older? Yes No
Have you been diagnosed with metastatic cancer that cannot be removed? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162